Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Inhibition of IL-23 mediated inflammation with a novel small molecule inverse agonist of RORgt.

Gauld S, Jacquet S, Gauvin D, Wallace C, Wang Y, McCarthy R, Goess C, Leys L, Huang S, Su Z, Edelmayer R, Wetter J, Salte K, McGaraughty S, Argiriadi M, Honore P, Luccarini JM, Bressac D, Desino K, Breinlinger E, Cusack K, Potin D, Kort M, Masson P.

J Pharmacol Exp Ther. 2019 Aug 2. pii: jpet.119.258046. doi: 10.1124/jpet.119.258046. [Epub ahead of print]

2.

Predicting the Need for a Tier II Ototoxicity Study From Early Renal Function Data.

Gauvin DV, Zimmermann ZJ, Yoder J, Tapp R, Baird TJ.

Int J Toxicol. 2019 Jul/Aug;38(4):265-278. doi: 10.1177/1091581819851232. Epub 2019 Jun 20.

PMID:
31220989
3.

NOEL and NOAEL: A retrospective analysis of mention in a sample of recently conducted safety pharmacology studies.

Baird TJ, Caruso MJ, Gauvin DV, Dalton JA.

J Pharmacol Toxicol Methods. 2019 Jun 17:106597. doi: 10.1016/j.vascn.2019.106597. [Epub ahead of print]

PMID:
31220592
4.

Extended recording of LMA in rats: Effects of IV catheters, "comfort jackets" and chamber lids on arterial blood gas parameters.

Gauvin DV, Zimmermann ZJ, Dalton JA, Baird TJ.

J Pharmacol Toxicol Methods. 2019 May 31:106594. doi: 10.1016/j.vascn.2019.106594. [Epub ahead of print]

PMID:
31158458
5.

Characterization of psoriasiform dermatitis induced by systemic injection of interleukin-23 minicircles in mice.

Leys L, Wang Y, Paulsboe S, Edelmayer R, Salte K, Wetter J, Namovic M, Phillips L, Dunstan R, Gauvin D, Donnelly-Roberts D, Su Z, Honore P, McGaraughty S.

J Dermatol. 2019 Jun;46(6):482-497. doi: 10.1111/1346-8138.14899. Epub 2019 May 7.

PMID:
31062408
6.

Monocytes/Macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation.

Wang Y, Edelmayer R, Wetter J, Salte K, Gauvin D, Leys L, Paulsboe S, Su Z, Weinberg I, Namovic M, Gauld SB, Honore P, Scott VE, McGaraughty S.

Sci Rep. 2019 Mar 29;9(1):5310. doi: 10.1038/s41598-019-41655-7.

7.

FOB vs modified Irwin: What are we doing?

Gauvin DV, Zimmermann ZJ.

J Pharmacol Toxicol Methods. 2019 May - Jun;97:24-28. doi: 10.1016/j.vascn.2019.02.008. Epub 2019 Mar 16. Review.

PMID:
30885703
8.

Establishing performance characteristics for positive control article selection in drug self-administration studies.

Gauvin DV, Zimmermann ZJ, Kallman MJ.

J Pharmacol Toxicol Methods. 2019 May - Jun;97:13-23. doi: 10.1016/j.vascn.2019.02.007. Epub 2019 Feb 21.

PMID:
30797952
9.

Relative equivalence of CNS safety (FOB) assessment outcomes in male and female Wistar-Han and Sprague-Dawley rats.

Gauvin DV, Dalton JA, Harter ML, Holdsworth D, May J, Tapp R, Zimmermann ZJ, Kilgus Q, Baird TJ.

J Pharmacol Toxicol Methods. 2019 Jan - Feb;95:2-11. doi: 10.1016/j.vascn.2018.11.002. Epub 2018 Nov 23.

PMID:
30476622
10.

In further defense of nonclinical abuse liability testing of biologics.

Gauvin DV, Zimmermann ZJ, Baird TJ.

Regul Toxicol Pharmacol. 2019 Feb;101:103-120. doi: 10.1016/j.yrtph.2018.11.009. Epub 2018 Nov 19. Review.

PMID:
30465804
11.

A reply to Henningfield, Fant & Wang (2018): regulatory action to control kratom is long overdue.

Gauvin DV, Zimmermann ZJ.

Psychopharmacology (Berl). 2019 Mar;236(3):861-863. doi: 10.1007/s00213-018-5112-4. Epub 2018 Nov 10. No abstract available.

PMID:
30415275
12.

"Not Everything That Shakes Is a Seizure": Making the Determination of Test Article-Induced Convulsions in Toxicology Studies.

Gauvin DV, Zimmermann ZJ, Yoder J, Baird TJ.

Int J Toxicol. 2018 Nov/Dec;37(6):422-433. doi: 10.1177/1091581818796444. Epub 2018 Sep 24. Review.

PMID:
30244632
13.

Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis; implications for drug discovery.

Gauld SB, Gauvin D, Olson L, Leys L, Paulsboe S, Liu Z, Edelmayer RM, Wetter J, Salte K, Wang Y, Huang S, Honore P, McGaraughty S.

J Dermatol Sci. 2018 Oct;92(1):45-53. doi: 10.1016/j.jdermsci.2018.08.001. Epub 2018 Aug 7.

PMID:
30149967
14.

The gold-standard in preclinical abuse liability testing: It's all relative.

Gauvin DV, Zimmermann ZJ, Baird TJ.

J Pharmacol Toxicol Methods. 2018 Nov - Dec;94(Pt 2):36-53. doi: 10.1016/j.vascn.2018.08.001. Epub 2018 Aug 18. Review.

PMID:
30125620
15.

Deriving A Drinking Water Guideline for A Non-Carcinogenic Contaminant: The Case of Manganese.

Valcke M, Bourgault MH, Haddad S, Bouchard M, Gauvin D, Levallois P.

Int J Environ Res Public Health. 2018 Jun 20;15(6). pii: E1293. doi: 10.3390/ijerph15061293.

16.

Discriminative stimulus effects of cocaine-levamisole combinations in Sprague-Dawley rats.

Zimmermann ZJ, Gauvin DV, Poling A.

J Psychopharmacol. 2018 Aug;32(8):900-910. doi: 10.1177/0269881118773545. Epub 2018 Jun 19.

PMID:
29916760
17.

A predictive index of biomarkers for ictogenesis from tier I safety pharmacology testing that may warrant tier II EEG studies.

Gauvin DV, Zimmermann ZJ, Yoder J, Harter M, Holdsworth D, Kilgus Q, May J, Dalton J, Baird TJ.

J Pharmacol Toxicol Methods. 2018 Nov - Dec;94(Pt 1):50-63. doi: 10.1016/j.vascn.2018.05.002. Epub 2018 May 8. Review.

PMID:
29751085
18.

Ototoxicity: The Radical Drum Beat and Rhythm of Cochlear Hair Cell Life and Death.

Gauvin DV, Yoder J, Zimmermann ZJ, Tapp R.

Int J Toxicol. 2018 May/Jun;37(3):195-206. doi: 10.1177/1091581818761128. Epub 2018 Mar 25. Review.

PMID:
29575954
19.

Public Health Consequences of Lead in Drinking Water.

Levallois P, Barn P, Valcke M, Gauvin D, Kosatsky T.

Curr Environ Health Rep. 2018 Jun;5(2):255-262. doi: 10.1007/s40572-018-0193-0. Review.

PMID:
29556976
20.

The drug discrimination assay: Interpretative value of partial generalization for drug schedule control actions.

Gauvin DV, Zimmermann ZJ, Code R, Baird TJ.

J Pharmacol Toxicol Methods. 2018 Mar - Apr;90:48-57. doi: 10.1016/j.vascn.2017.11.005. Epub 2017 Dec 11.

PMID:
29203450
21.

Down for the count: The critical endpoint in ototoxicity remains the cytocochleogram.

Gauvin DV, Yoder J, Koch A, Zimmermann ZJ, Tapp RL.

J Pharmacol Toxicol Methods. 2017 Nov - Dec;88(Pt 2):123-129. doi: 10.1016/j.vascn.2017.09.254. Epub 2017 Sep 18. Review.

PMID:
28927990
22.

NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential.

Miyazaki T, Choi IY, Rubas W, Anand NK, Ali C, Evans J, Gursahani H, Hennessy M, Kim G, McWeeney D, Pfeiffer J, Quach P, Gauvin D, Riley TA, Riggs JA, Gogas K, Zalevsky J, Doberstein SK.

J Pharmacol Exp Ther. 2017 Oct;363(1):104-113. doi: 10.1124/jpet.117.243030. Epub 2017 Aug 4.

PMID:
28778859
23.

Indoor swimming pool environments and self-reported irritative and respiratory symptoms among lifeguards.

Bureau G, Lévesque B, Dubé M, Gauvin D, Lépine F, Laliberté D.

Int J Environ Health Res. 2017 Aug;27(4):306-322. doi: 10.1080/09603123.2017.1342228. Epub 2017 Jun 25.

PMID:
28649872
24.

Comparison of lidocaine and lidocaine-epinephrine for the paravertebral brachial plexus block in dogs.

Choquette A, Del Castillo JRE, Moreau M, Guillot M, Alexander K, Kona-Boun JJ, Gauvin D, Troncy E.

Vet Anaesth Analg. 2017 Mar;44(2):317-328. doi: 10.1016/j.vaa.2016.08.002. Epub 2017 Jan 11.

PMID:
28461127
25.

Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis.

Monteiro BP, Klinck MP, Moreau M, Guillot M, Steagall PV, Pelletier JP, Martel-Pelletier J, Gauvin D, Del Castillo JR, Troncy E.

PLoS One. 2017 Apr 12;12(4):e0175565. doi: 10.1371/journal.pone.0175565. eCollection 2017.

26.

Method of data interpretation for the determination of abuse liability in rodent self-administration studies under the FDA guidance document.

Gauvin DV, Zimmermann ZJ, Baird TJ.

J Pharmacol Toxicol Methods. 2017 Jul;86:44-59. doi: 10.1016/j.vascn.2017.03.002. Epub 2017 Mar 15. Review.

PMID:
28315739
27.

Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.

Born S, Gauvin DV, Mukherjee S, Briscoe R.

Regul Toxicol Pharmacol. 2017 Jun;86:181-192. doi: 10.1016/j.yrtph.2017.03.006. Epub 2017 Mar 6.

PMID:
28279667
28.

Repeated "Day 1" FOB testing in ICH S7A safety assessment protocols: The influence of within- and between-session learning.

Gauvin DV, Zimmermann ZJ, Dalton JA, Baird TJ.

J Pharmacol Toxicol Methods. 2017 May - Jun;85:61-72. doi: 10.1016/j.vascn.2017.02.018. Epub 2017 Feb 12. Review.

PMID:
28216425
29.

Current FDA regulatory guidance on the conduct of drug discrimination studies for NDA review: Does the scientific literature support recent recommendations?

Gauvin DV, Zimmermann ZJ, Kallman MJ.

Drug Alcohol Depend. 2016 Nov 1;168:307-319. doi: 10.1016/j.drugalcdep.2016.08.013. Epub 2016 Aug 13. Review.

PMID:
27629024
30.

The standardized functional observational battery: Its intrinsic value remains in the instrument of measure: The rat.

Gauvin DV, Yoder JD, Holdsworth DL, Harter ML, May JR, Cotey N, Dalton JA, Baird TJ.

J Pharmacol Toxicol Methods. 2016 Nov - Dec;82:90-108. doi: 10.1016/j.vascn.2016.08.001. Epub 2016 Aug 14. Review.

PMID:
27534836
31.

Concurrent validity of different functional and neuroproteomic pain assessment methods in the rat osteoarthritis monosodium iodoacetate (MIA) model.

Otis C, Gervais J, Guillot M, Gervais JA, Gauvin D, Péthel C, Authier S, Dansereau MA, Sarret P, Martel-Pelletier J, Pelletier JP, Beaudry F, Troncy E.

Arthritis Res Ther. 2016 Jun 23;18:150. doi: 10.1186/s13075-016-1047-5.

32.

Small Compartment Toxicity: CN VIII and Quality of Life: Hearing Loss, Tinnitus, and Balance Disorders.

Gauvin DV, Yoder JD, Tapp RL, Baird TJ.

Int J Toxicol. 2017 Jan 1;36(1):8-20. Epub 2016 May 18.

PMID:
27194512
33.

Functional and transport analyses of CLCN5 genetic changes identified in Dent disease patients.

Tang X, Brown MR, Cogal AG, Gauvin D, Harris PC, Lieske JC, Romero MF, Chang MH.

Physiol Rep. 2016 Apr;4(8). pii: e12776. doi: 10.14814/phy2.12776.

34.

Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists.

Gomtsyan A, Schmidt RG, Bayburt EK, Gfesser GA, Voight EA, Daanen JF, Schmidt DL, Cowart MD, Liu H, Altenbach RJ, Kort ME, Clapham B, Cox PB, Shrestha A, Henry R, Whittern DN, Reilly RM, Puttfarcken PS, Brederson JD, Song P, Li B, Huang SM, McDonald HA, Neelands TR, McGaraughty SP, Gauvin DM, Joshi SK, Banfor PN, Segreti JA, Shebley M, Faltynek CR, Dart MJ, Kym PR.

J Med Chem. 2016 May 26;59(10):4926-47. doi: 10.1021/acs.jmedchem.6b00287. Epub 2016 May 2.

PMID:
27077528
35.

Analgesic efficacy of an oral transmucosal spray formulation of meloxicam alone or in combination with tramadol in cats with naturally occurring osteoarthritis.

Monteiro BP, Klinck MP, Moreau M, Guillot M, Steagall PV, Edge DK, Pelletier JP, Martel-Pelletier J, Gauvin D, Del Castillo JR, Troncy E.

Vet Anaesth Analg. 2016 Nov;43(6):643-651. doi: 10.1111/vaa.12360. Epub 2016 Feb 24.

PMID:
26913836
36.

Exposure to cyanobacteria: acute health effects associated with endotoxins.

Lévesque B, Gervais MC, Chevalier P, Gauvin D, Anassour-Laouan-Sidi E, Gingras S, Fortin N, Brisson G, Greer C, Bird D.

Public Health. 2016 May;134:98-101. doi: 10.1016/j.puhe.2015.11.027. Epub 2016 Jan 14. No abstract available.

PMID:
26775854
37.

Paracrine Wnt1 Drives Interstitial Fibrosis without Inflammation by Tubulointerstitial Cross-Talk.

Maarouf OH, Aravamudhan A, Rangarajan D, Kusaba T, Zhang V, Welborn J, Gauvin D, Hou X, Kramann R, Humphreys BD.

J Am Soc Nephrol. 2016 Mar;27(3):781-90. doi: 10.1681/ASN.2014121188. Epub 2015 Jul 23.

38.

Preclinical assessment of abuse liability of biologics: In defense of current regulatory control policies.

Gauvin DV, Zimmermann ZJ, Baird TJ.

Regul Toxicol Pharmacol. 2015 Oct;73(1):43-54. doi: 10.1016/j.yrtph.2015.06.009. Epub 2015 Jun 21. Review.

PMID:
26107292
39.

Investigation of Air Quality Problems in an Indoor Swimming Pool: A Case Study.

Lévesque B, Vézina L, Gauvin D, Leroux P.

Ann Occup Hyg. 2015 Oct;59(8):1085-9. doi: 10.1093/annhyg/mev038. Epub 2015 Jun 19.

PMID:
26091681
40.

The failure to detect drug-induced sensory loss in standard preclinical studies.

Gauvin DV, Abernathy MM, Tapp RL, Yoder JD, Dalton JA, Baird TJ.

J Pharmacol Toxicol Methods. 2015 Jul-Aug;74:53-74. doi: 10.1016/j.vascn.2015.05.011. Epub 2015 Jun 2. Review.

PMID:
26045062
41.

Utility of the auditory brainstem response evaluation in non-clinical drug safety evaluations.

Abernathy MM, Gauvin DV, Tapp RL, Yoder JD, Baird TJ.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:111-7. doi: 10.1016/j.vascn.2015.05.005. Epub 2015 May 14. Review.

PMID:
25981377
42.

Abuse liability assessment of hydrocodone under current draft regulatory guidelines.

Gauvin DV, McComb M, Code R, Dalton JA, Baird TJ.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:118-29. doi: 10.1016/j.vascn.2015.05.003. Epub 2015 May 9.

PMID:
25969422
43.

The IVAIRE project--a randomized controlled study of the impact of ventilation on indoor air quality and the respiratory symptoms of asthmatic children in single family homes.

Lajoie P, Aubin D, Gingras V, Daigneault P, Ducharme F, Gauvin D, Fugler D, Leclerc JM, Won D, Courteau M, Gingras S, Héroux MÈ, Yang W, Schleibinger H.

Indoor Air. 2015 Dec;25(6):582-97. doi: 10.1111/ina.12181. Epub 2015 Jan 21.

PMID:
25603837
44.

A medicinal herb-based natural health product improves the condition of a canine natural osteoarthritis model: a randomized placebo-controlled trial.

Moreau M, Lussier B, Pelletier JP, Martel-Pelletier J, Bédard C, Gauvin D, Troncy E.

Res Vet Sci. 2014 Dec;97(3):574-81. doi: 10.1016/j.rvsc.2014.09.011. Epub 2014 Sep 28.

PMID:
25311158
45.

Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.

Voight EA, Gomtsyan AR, Daanen JF, Perner RJ, Schmidt RG, Bayburt EK, DiDomenico S, McDonald HA, Puttfarcken PS, Chen J, Neelands TR, Bianchi BR, Han P, Reilly RM, Franklin PH, Segreti JA, Nelson RA, Su Z, King AJ, Polakowski JS, Baker SJ, Gauvin DM, Lewis LR, Mikusa JP, Joshi SK, Faltynek CR, Kym PR, Kort ME.

J Med Chem. 2014 Sep 11;57(17):7412-24. doi: 10.1021/jm500916t. Epub 2014 Aug 21.

PMID:
25100568
46.

Exposure of young children to household water lead in the Montreal area (Canada): the potential influence of winter-to-summer changes in water lead levels on children's blood lead concentration.

Ngueta G, Prévost M, Deshommes E, Abdous B, Gauvin D, Levallois P.

Environ Int. 2014 Dec;73:57-65. doi: 10.1016/j.envint.2014.07.005. Epub 2014 Aug 2.

47.

Association between sensitisation and pain-related behaviours in an experimental canine model of osteoarthritis.

Rialland P, Otis C, Moreau M, Pelletier JP, Martel-Pelletier J, Beaudry F, Del Castillo JR, Bertaim T, Gauvin D, Troncy E.

Pain. 2014 Oct;155(10):2071-9. doi: 10.1016/j.pain.2014.07.017. Epub 2014 Jul 27.

PMID:
25075591
48.

Sulfate but not thiosulfate reduces calculated and measured urinary ionized calcium and supersaturation: implications for the treatment of calcium renal stones.

Rodgers A, Gauvin D, Edeh S, Allie-Hamdulay S, Jackson G, Lieske JC.

PLoS One. 2014 Jul 25;9(7):e103602. doi: 10.1371/journal.pone.0103602. eCollection 2014.

49.

Assessing experimental visceral pain in dairy cattle: A pilot, prospective, blinded, randomized, and controlled study focusing on spinal pain proteomics.

Rialland P, Otis C, de Courval ML, Mulon PY, Harvey D, Bichot S, Gauvin D, Livingston A, Beaudry F, Hélie P, Frank D, Del Castillo JR, Troncy E.

J Dairy Sci. 2014;97(4):2118-34. doi: 10.3168/jds.2013-7142. Epub 2014 Feb 15.

50.

Background variability in standard clinical pathology biomarkers in beagle dogs instrumented with chronic indwelling telemetry devices.

Baird TJ, Aulbach A, O'Donohue KP, Yoder JD, Dalton JA, Gauvin DV.

J Pharmacol Toxicol Methods. 2014 May-Jun;69(3):223-8. doi: 10.1016/j.vascn.2014.01.005. Epub 2014 Feb 5.

PMID:
24508734

Supplemental Content

Loading ...
Support Center